Chargement en cours...
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Artesunate is such a preferred candidate, because artesunate is clinically well-tolerated and m...
Enregistré dans:
| Publié dans: | Acta Pharmacol Sin |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Singapore
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8026986/ https://ncbi.nlm.nih.gov/pubmed/32699265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-020-0478-3 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|